In the wake of healthcare reform, pharmaceutical executives help take charge.
Pharmaceutical executives’ role in healthcare reform is a far cry from 15 years ago during the Clinton administration, when they helped defeat President Clinton’s reform efforts. Today they are trying to steer lawmakers away from measures that could reduce drug margins, pressing instead for cost reductions by hospitals and insurers, the Wall Street Journal reports.
As the United States grapples with reining in healthcare costs, some focus for savings should be placed on the infrastructure and processes that have complicated the delivery and administration of healthcare benefits, according to Robert Taketomo, PharmD, president and CEO of Ventegra, Glendale, Calif.
“Care should be taken to ensure that actual providers of patient care and manufacturers of hard products-including healthcare supplies and drugs are not unduly compromised,” Taketomo says. “Great savings, and higher quality of care, can be achieved if we can manage a more efficient process for putting the ultimate buyers and sellers of healthcare products and services together in a more transparent and efficient manner.”